Loading viewer...
investor_presentation
Format: PDF investor_presentation
Halozyme is a profitable biopharma company focused on its proprietary ENHANZE® drug delivery platform combined with autoinjector device technology. The company projects 2022 revenue of $655-685 million, representing 48-55% growth, driven by diverse revenue streams including partner collaborations and commercialized products.
investor_presentation
18 Pages
investor_presentation
54 Pages
Experian
Exact Sciences Cologuard Corporate Presentation 2016
investor_presentationinvestor_presentation
37 Pages
Exact Sciences Corporation
